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Abstract 
Epigenetic chromatin remodeling and signalling pathways play an integral role in the 
transcription dependent neurodegeneration and long-term potentiation (LTP), a 
cellular model associated with learning and memory. Pathological epigenetic 
modifications associating with neurological disorders are inherently flexible and can 
be reversed through pharmacological interventions. Small molecules are the favored 
drugs for clinicians, and in neurological disorders associated with complex cellular 
mechanisms, epigenetic and/or signalling pathway enzyme inhibiting small molecules 
have shown clinical prospects. Recently, small molecules with two or more functional 
activities such as sequence-specific recognition and signalling pathway and/or 
enzyme modulation have shown the capability as efficient transcriptional activators. 
Here, we give a balanced overview of the key factors associated with memory 
recovery and neurodegeneration, available chemical tools for modulation and the 
demand to develop next-generation small molecules with multi-functional activities to 













More small molecules enter the clinic as new drugs than any other drugs such as 
vaccines, peptides, and siRNA.1 Modern biological and analytical techniques assist us 
to attain huge biological information, which can be harnessed to devise novel 
therapeutic strategies for some complex disorders such as neurological diseases.2 
Information is not only a powerful but also a critical resource that needs meticulous 
management and regulation. In living systems, DNA serves as the informational 
molecule that can store and retrieve the genetic instructions conferring the 
development and characteristics of all known living organisms.3,4 The term ‘memory’ 
could be defined as the process by which the information gets encrypted, accumulated, 
and recovered. From a functional point of view, memory is relevant to DNA because 
both encode, store and retrieve information and function as rewritable data storage in 
living cells.5 Depending on the mode, duration and capacity of storage, memory can 
be broadly classified into three types: 1) sensory memory, 2) short-term memory and 
3) long-term memory.6 Long-term memory and its storage at the cellular level are 
associated with gene transcription/translation. Also, studies using protein synthesis 
inhibitors have further verified this phenomenon as only the enduring memories were 
blocked.7 Cognitive processes like learning and memory are often associated with 
Long-term potentiation (LTP), a process that modulates the changes in neural 
synapses by enhancing the signal strength between neurons.8 Based on the distinctive 
molecular mechanisms, LTP gets categorized into two phases. The transcription 
independent early phase that lasts for about 3 hours while the 
transcription/translation- dependent late phase can last up to even several weeks under 
in vivo conditions.9 Interestingly, this transcription dependency aspect of LTP is 
analogous with memory. N-methyl-d-aspartate (NMDA) and its action on its 
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receptors steer the influx of calcium and initiate phosphorylation of ERK 
(extracellular signal-regulated kinase), which in turn induces and maintains LTP.9 
Studies with various histone deacetylase (HDAC) inhibitors and neural development 
have shown that in most cases, enrichment of the total acetylation rates in the brain 
can lead to an increased rate of transcription, which in turn can aid the memory 
process.10,11 CREB, a cAMP response element and transcriptional activator, bind with 
the transcriptional co-activator CBP (CREB-binding protein) to form a CREB:CBP 
complex for the activation of the target hippocampus-dependent, long-term memory 
associated genes.12 Haettig et al. implied the essential role of CBP through studies in 
mouse behavioural models where the HDAC inhibition was shown to modulate long-
term memory for object recognition.13  Their studies with systemic delivery of a 
HDAC inhibitor also suggested that different chromatin-modifying enzymes control 
distinctive memory-related genes in different brain regions. Although neurons are 
non-proliferating and terminally differentiated cells, the cellular proliferation- and 
differentiation-associated proteins, and protein kinase cascades were shown to be vital 
for long-term memory formation.9,14-17 Recent developments in functional genomics 
reveal the essential role of noncoding RNAs (ncRNAs) in the regulation of chromatin 
remodelling, which control the transcriptional programs conferring to LTP.18 The 
ncRNAs are generally accepted to contribute towards the intricacy and function of the 
mammalian brain.19 The ncRNAs play a vital role in LTP and are found more 
predominantly in the nervous system.20 For example, Scott et al.. demonstrated 
through expression and functional deficit studies that miR-132 could co-ordinate the 
intricate transcriptional machinery associated with the synaptic mechanisms 
controlling the memory formation.21 Thus, despite extensive available literature, it is 
hard to generalize cellular and molecular mechanisms conferring the inception, 
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consolidation, and retention of memory. The existing information regarding memory-
associated mechanisms is acquired through studies on neurological disorders.22 
Several studies with HDAC-inhibiting small molecules have substantiated the 
essential role of epigenetics and transcriptional activation in memory formation and 
neurological disorders.23 Because alterations in epigenetic program are merely a small 
part of a huge complicated interaction of signalling pathways controlling the 
mechanism of LTP expression, a comprehensive overview of the molecular 
mechanisms underlying LTP is beyond the scope of this review.  
 In this review, we give a brief overview of the epigenetic aspect of 
transcription dependent LTP, an underlying cellular phenomenon associated with 
several neurological disorders. Also, by summarizing the potential of individual 
available bioactive small molecules, we suggest the importance of developing next 
generation small molecules with multiple activities such as i) HDAC inhibition, ii) 
signaling factor inhibition, iii) sequence-specific recognition, and iv) other such 
biologically significant properties. Development of such doubly active or multi-target 
small molecules can have a significant impact in elucidating the molecular 
mechanisms such as LTP, which in turn may lead to effective treatment for complex 
neurological disorders. 
 
2. Long-term potentiation and memory  
2.1. Long-term potentiation – A brief overview 
Neurons are the fundamental building blocks of the nervous system, which manages 
the intricate organization of how humans sense, perceive, and act. Santiago Ramón y 
Cajal, an eminent neuroanatomist24 first proposed that memories could be formed by 
improving the efficacy of neural communication through strengthening of the 
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connections between existing neurons. In 1949, Donald Hebb reiterated this view and 
proposed a theory that cells develop fresh connections or undergo metabolic changes 
to enhance the communication capacity.25 In 1966, Terje Lømo discovered the 
process of long-term potentiation through a series of neurophysiological experiments 
on anesthetized rabbits and explored the relationship between short-term memory and 
the role of the hippocampus, a region long known to be essential for learning and 
memory.26 Subsequent reports characterized this phenomenon, and in 1975, Douglas 
and Goddard termed this phenomenon “long-term potentiation or LTP”.27 LTP occurs 
in other neural structures like the cerebral cortex, cerebellum and amygdala in the 
mammalian brain.28 Since different areas of the brain exhibit different forms of LTP, 
many factors such as age and anatomical location influence the specific type of 
LTP.29 For studies on mammalian LTP, the CA1 hippocampus gets preference owing 
to its predictable organization and readily inducible LTP.28 LTP gains prominence 
over other kinds of synaptic plasticity owing to its ability to persist and last from 
several minutes to months.30 Activation of NMDA receptors in hippocampal neurons 
trigger early phase LTP through the activation of calcium-dependent kinases and 
involves an increase in the synaptic AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) receptor function.31 While early phase LTP is independent of 
protein synthesis, late phase LTP requires the persistent activity of atypical protein 
kinase C isoform (PKMζ) for active synaptic transmission in the central nervous 
system and to maintain an increased amount of AMPA receptors at potentiated 
synapses to consolidate memory.32 Transcription factors like Zif 268 are suggested to 
trigger the signalling of PKMζ gene activation.33 Whitlock et al. demonstrated 
through inhibitory avoidance learning experiments in rats that learning induces 
similar changes in hippocampal glutamate receptors like those observed in high 
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frequency stimulation-inducted LTP.34 
 
2.2. LTP in neurological disorders 
Impaired long-term potentiation plays an important role in the pathology of many 
neurodegenerative disorders that can be either progressive or immediate. Alzheimer’s 
disease (AD) is an extensively studied progressive neurodegenerative disease 
characterized by the abnormal processing of amyloid precursor protein (APP), 
hyperphosphorylation of tau protein, apoptotic-like cell death, cognitive decline and 
defective memory.35 Synaptic loss and dysfunction are the two main features 
associated with the cognitive decline in AD, which are attributed to soluble amyloid 
beta (Aβ) in the brain of AD patients. Aβ oligomers inhibit LTP and facilitate long 
term depression, a slow, weak electrical stimulation of CA1 neurons that reduce the 
number of AMPA receptors at the synapse.36 In addition, there are reports that AD 
impairs LTP by the accumulation of the enzyme protein kinase M zeta (PKMζ) in 
neurofibrillary tangles suggesting a link between PKMζ-mediated synaptic plasticity 
and memory impairment in AD.37 On account of the fact that AD is still incurable, a 
deeper understanding of the complex mechanisms such as epigenetic dysfunction 
associated with this neurodegenerative disease is of increasing importance.38 Graff et 
al. showed that the hippocampus region in human AD brain has elevated levels of 
HDAC2, the enzyme known to modulate gene transcription associated with 
learning.39 Therefore, developing strategies to alter the epigenetic program could be 
useful in treating AD. 
 Huntington’s disease (HD) is an autosomal dominant neurodegenerative 
disorder that is characterized with the progressive motor dysfunction, dementia, and 
psychiatric disturbance. Genetic and phenotypic studies of animal models of HD 
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reveal certain LTP alterations. Crupi et al. discussed the possibility of the damage of 
LTP-like plasticity due to the alterations of the neuronal circuits in HD patients.40 
Dallerac et al. showed that the D1 dopamine receptor activation rescued the impaired 
LTP in the mouse model of HD disease.41 Costa et al. showed that L-DOPA restores 
the hippocampal synaptic potentiation through D1/D5 receptors and improves the 
cognitive deficit in experimental models of Parkinson’s disease.42 Transcriptional 
abnormalities leading to neuronal damage in HD are often associated with epigenetic 
alterations. The epigenetic enzymes known to control gene transcription such as 
DNMT and HDAC have been envisaged as potential therapeutic targets in HD 
treatment.43 Other major disorders include amnesia, where memory and learning are 
affected among other cognitive functions, and agnosia, which is characterized by the 
inability to recognize certain objects, persons, or sounds. Because the loss of 
cognition is the common manifestation of these neurological disorders, strategies to 
regulate LTP could aid us to gain insights into general cellular mechanisms and 
facilitate strategies to treat cognitive impairment.  
 
2.3. Transcription factor-mediated reprogramming for neurogenesis and cell 
replacement therapy 
Neurogenesis, a dynamic cellular process that validates the precise functioning of 
learning and memory processes could be achieved through the activation of cell fate 
specific transcription factors. Watanabe et al. showed the conversion of C2C12 
myoblasts into neurons by overexpressing a recombinant form of REST (REST-
VP16), which contains the transcriptional activation domain of the herpes simplex 
virus protein VP16.44 Vierbuchen et al. reprogrammed mouse embryonic and 
postnatal fibroblast cells into neurons by ectopic expression of three transcription 
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factors Ascl1, Brn2, and Myt1l.45 Neural stem cells (NSCs) that are capable of self-
renewal or differentiation can generate new neurons and have a debatable role in 
alleviating the memory loss after getting transplanted in transgenic mouse AD 
models.46 An essential role of BDNF (brain derived neurotrophic factor) for the 
functional effect of transplanted NSCs was demonstrated in a study that clearly 
showed that only the rats that received stem cells and BDNF and not the control 
animals, preserved learning and memory.47 Some of the LTP associated genes/factors, 
which are the potential targets of cellular reprogramming and their characterized role 
in human and animal models are listed in Table 1.48-56 
Table 1. 
 Along with some of these key signal transduction factors, epigenetic 
modifications also got associated with cognitive recognition.57 
 
3. Epigenetic enzyme inhibitors for transcriptional 
activation  
3.1. HDAC and DNMT inhibiting small molecules for memory recovery 
There are two major epigenetic mechanisms involved in learning and memory: 1) 
modification at cytosines in CpG dinucleotide sequences by methylation; and 2) 
chromatin remodelling. Studies with animal models using different learning and 
memory methods, 58 and with a post-mortem of the human brain59 to endorse this 
phenomenon. The methylation of both DNA and the histone proteins has been 
implicated in LTP and memory formation60. DNA methylation inducing DNA methyl 
transferases (DNMTs) such as DNMT1, DNMT3a, and DNMT3b are differentially 
expressed within the adult brain and suggest its critical role in cognition.61 Recent 
studies have shown that by blocking DNMT activity with inhibitors 5-AZA-dC and 
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zebularine, contextual fear-conditioned memory formation could be disrupted.62 
DNMT inhibition also resulted in increased expression level of the memory-
stimulating gene Reelin through promoter demethylation whereas a decreased 
expression level of memory-suppressing genes like PPI1 was also observed.63 Taken 
together, it is evident that epigenetic regulation of memory promoting genes form a 
complex pattern as these processes cross-talk, interact with, and influence each other.  
      HDAC enzymes govern the gene transcription by conserving them in 
heterochromatin architecture and regulating the chromatin-remodelling event. Histone 
deacetylase inhibitors (HDACi) like trichostatin A (TSA) and vorinostat 
[suberoylanilide hydroxamic acid (SAHA)] are capable of inhibiting HDACs with 
varying efficiency (at nanomolar to millimolar concentrations) and causes 
hyperacetylation of histones, which in-turn triggers transcriptional activation of 
certain genes through relaxation of the DNA conformation.64 However, HDAC 
inhibition always does not always restore the transcription of the gene under 
investigation. For instance, Lopez-Atalaya et al. showed through chromatin immune 
precipitation sequencing and gene expression profiling studies that TSA had only a 
moderate effect on hippocampal gene expression.65 Proteins other than histones can 
be deacetylated by HDACs owing to the involvement of HDACs in many complex 
cellular processes.66,67 Prolonged treatment of adult rat neural progenitors with 
valproic acid (VPA), a known HDAC inhibitor, resulted in the reduced proliferation 
of adult neural progenitors, but observed an increase in neuronal differentiation.68 
Further examinations showed an increase in the Neurod1 mRNA level, a transcription 
factor required for the neuronal differentiation after VPA treatment.69 Yu et al. 
showed that VPA intensely repressed the proliferation of progenitor cells and 
increased the neuronal differentiation by inducing the expression of proneuronal 
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transcription factors such as Ngn1, Math1, and p15 that contribute to neuronal 
differentiation.70 VPA has also been shown to effectively block the aberrant 
neurogenesis and prevent the hippocampal seizures induced cognitive impairment.71 
Kim et al. showed that neurogenesis is stimulated in the brain of ischemic rat models 
with NaB treatment.72 Overall, HDACi positively regulate differentiation of newborn 
neurons and has a potential in treating cognitive impairment.73 Also, a number of 
inhibitor-based experiments verified that HDACs can negatively regulate long-term 
memory formation.74,75 Recent studies on individual HDACs and their effects on LTP 
have revealed that HDAC2, and not HDAC1, is a key HDAC for regulating memory 
formation.76 HDAC3 is also known to negatively regulate memory formation.77 Table 
2 details the enzymes that are associated with a specific neurological disorder.78-82 
Table 2. 
      The process of aging results in reduced acetylation of histones H3 and H4 in the 
promoter regions of the BDNF gene to suppress its expression and significantly 
contribute to the deficits in hippocampal synaptic structure and function.83 These 
changes can be repaired by HDAC inhibition or selective activation of trkB receptors. 
Taken together, a chromatin-modifying enzyme like HDAC is a potential therapeutic 
target that can generate a form of long-term memory, which persists beyond a point at 
which normal memory fails (Fig. 1).    
(Fig. 1) 
3.2. Therapeutic potential of HDACi in memory recovery 
Pharmacological intervention of histone acetylation using HDACi has been useful to 
treat memory impairment in neurodegenerative disorders and to enhance cognition.84 
However, the therapeutic use of HDACi needs careful validation as studies in mice 
and some observations in patients have shown that memory-related processes could 
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be impaired with chronic HDAC inhibition.85-87 By forming a complex with HDACs, 
methyl-CpG binding protein 2 (Mecp2) is believed to act as a transcriptional 
modulator in the basolateral amygdala (BLA) and is required for normal anxiety 
behaviour as well as certain types of learning and memory.88 Adachi et al. suggested 
the key role of Mecp2 as a transcriptional repressor in Rett Syndrome, an X-linked 
neurodevelopmental disorder.89 By infusing SAHA, they explored the effect of 
histone H3 acetylation on the anxiety phenotype of BLA-specific MECP2 knockdown 
mice. However, the SAHA infused mice demonstrated increased anxiety like 
behaviour and impaired cue-dependent fear learning. This result is in contrast with 
that observed with a single drug dose, and the saturation of changes in neuronal 
plasticity due to the chronically elevated histone acetylation was hinted to be the 
reason.89 Since anxiety is a complex behaviour that is mediated by a combination of 
genes, SAHA may have targeted other genes not regulated by MeCP2. Hence, these 
molecules should be designed with the ability to recognize specific region(s) in the 
brain as genes and systems required for LTP maintenance in one brain-region may not 
be required in the other. These findings demonstrate a potential shortcoming of 
employing the HDACis such as SAHA to recover memory as they may produce 
undesirable psychiatric behavioural side effects and warrants the need for customizing 
them to induce specific genes.  
 
3.3. Therapeutic potential of HDACi in neurological disorders 
Memory loss and cognitive dysfunction are not typical characteristics of Friedrich’s 
ataxia (FRDA), a neurodegenerative disease caused by transcriptional repression of 
the FXN gene encoding the essential mitochondrial protein, Frataxin.90 However, 
chemical approaches developed to treat this transcription dependent disorder could be 
 13 
mimicked for memory related disorders. For example, HDACis like SAHA, TSA, and 
sodium butyrate had no notable effect on FXN transcription in non-FRDA cells. 
However, the commercially available HDACi BML-210 and its derivative efficiently 
induced the silenced FXN gene in lymphoid cell lines derived from FRDA patients 
and increased the level of Frataxin in cells.91 In neurodegenerative HD, aberrant 
transcription caused by the mutant huntingtin involves functionally defective 
transcription factors and coactivators like CBP, which impair the CBP/CREB 
mediated gene expression and histone deacetylation.92,93 Steffan et al. suggested the 
therapeutic potential of a HDACi in HD, as the use of HDACi inhibited the 
polygultamine-dependent neuronal degeneration and reduced lethality in a Drosophila 
model.94 Subsequently, Ferrante et al. showed that the HDACi sodium butyrate 
triggered specificity protein-1 acetylation, and ameliorated the neurodegenerative 
phenotype in R6/2 transgenic mouse model of HD.80 Administration of the HDACi 
phenylbutyrate at tolerable doses caused significant neuroprotective effects in the 
N171-82Q transgenic mouse model of HD.95 Preclinical trial experiments carried out 
in R6/2 HD mouse model showed that the HDACi SAHA ameliorated motor deficits 
by crossing the blood-brain barrier and increasing the histone acetylation in the 
brain.96 
      Genome-wide gene analysis through microarray studies showed that the chronic 
oral administration of HDACi 4b, an analog of BML-210 reversed histone H3 
hypoacetylation and ameliorated the disease phenotype and transcriptional 
abnormalities in HD transgenic mice.97 Conversely, Beconi et al. demonstrated the 
shortcomings in the potential employment of pimelic diphenylamide HDACi to treat 
neurological disorders.98 Evaluation of HDAC isoform selectivity, cellular activity, in 
vitro and in vivo ADME (absorption, distribution, metabolism and excretion) 
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properties of 4b have revealed that even when in vitro selectivity and binding mode 
were in agreement with previous reports,98 their physicochemical stability and 
metabolic characteristics casted serious doubts that CNS HDAC3 inhibition is a 
therapeutic target for HD.97 Hence, 4b was unsuitable as a molecular tool to examine 
class I HDAC inhibition in vivo and the need for proper ADME assessment of 
compounds before the in vivo target validation and therapeutic application was 
proposed. Specificity and off-target effects are the key issues that hamper the 
employment of small molecules in biological studies. Many studies tend to focus on 
target genes but ignore changes in the expression of other genes. Because the small 
molecules used (e.g. TSA, SAHA, VPA) in the experiments could also hit other 
targets not related to chromatin-remodeling or epigenetic regulation. This is often the 
case when unreasonably high concentrations of drugs were used. In this regard, there 
has been a rising demand for programmed small molecules targeting specific gene(s).  
 
3.4. Programmable DNA binding small molecules in neurological disorders 
DNA stores heritable information over a long period of time using only four 
nucleobases. Hence, small molecules interacting with these nucleobases can 
significantly alter the mutations that confer a specific neurological disorder. N-
methylpyrrole-N-methylimidazole polyamides (PIPs) are cell-permeable small 
molecules capable of binding to the minor groove of DNA with an affinity that is 
comparable to that of transcription factors.99 PIPs bind to DNA following a binding 
rule, where an antiparallel pairing of I opposite P (I/P) recognizes a G–C base pair, 
while a P/P pair recognizes A–T or T–A base pairs. Synthetic PIPs possessing an 
alkylating moiety have been successfully employed for selective gene silencing and to 
target cancer associated mutations.100,101 The interference of PIPs with transcription 
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factors also has a positive induction effect, which suggests that PIPs can inhibit both 
basal and activated transcription. DNA-binding sequence-specific PIPs can potentially 
be used to reverse the effects and alter the FXN gene by targeting GAA TTC 
repeats.102 For a practical demonstration, Burnett et al. synthesized a PIP (P1) to 
target the 9-bp sequence, as in the GAA TTC repeat DNA sequence. These 
polyamides bound to the coding region of the gene without affecting transcription in 
mammalian cells. When polyamide P1-treated cell lines were taken from an FRDA 
patient who had a very low level (6%–13%) of Frataxin protein and the results were 
compared with an unaffected sibling, it was found that the polyamide P1 increased the 
FXN transcription by about 2–3-fold. Similar treatment with a mismatch polyamide 
showed a modest result. A recent study by Dervan and colleagues has shown that 
these polyamides do not fit into single-stranded RNA or duplex regions of RNA to 
suggest a lack of effect on the translation of Frataxin mRNA.103 
 
4.  Small Molecules with Dual Characteristics: Progress and 
Prospects 
4.1. Sequence-specific epigenetic activators  
Recently, some novel strategies have emerged to achieve small molecules with 
versatile properties. One such novel small molecule termed SAHA-PIP encompasses 
both selective DNA-binding hairpin pyrrole–imidazole polyamides (PIPs) and the 
potent HDAC inhibitor, SAHA (Fig. 2A). The biological activity of SAHA-PIP was 
first demonstrated by synthesizing SAHA-PIPs that could sequence-specifically 
acetylate the promoter region of the tumour suppressor gene p16 in HeLa cells.104 
When the effects of a library of distinct SAHA-PIPs were evaluated on the epigenetic-
dependent and complicated pluripotency gene network in mouse embryonic 
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fibroblasts (MEFs), certain SAHA-PIPs differentially induced pluripotency genes 
through the initiation of epigenetic marks that confer transcription accommodating 
chromatin including histone H3 Lys9 and Lys14 acetylation.105,106 (Fig. 2B). An 
advanced version of SAHA-PIP termed, `δ` but not SAHA, rapidly induced multiple 
pluripotency genes.107 Interestingly, δ-OMe, the non-functional SAHA-PIP did not 
activate any pluripotency genes to validate SAHA as the functional moiety in δ. 
Because SAHA-PIP encompasses both HDAC inhibitory activity and sequence-
specific binding ability, interpretation of a definite mechanism is challenging. About 
33% of the δ-induced genes belonged to the core pluripotency gene network that 
comprises of 345 inter-twined genes. Hence, it is reasonable to assume that the PIP in 
δ directs SAHA to the typically conserved core pluripotency gene network for site-
specific epigenetic modifications (Fig. 2B). Analysis of the number of matching sites 
in the Nanog gene further substantiates this notion.105 However, more studies are 
warranted to have a thorough understanding of the SAHA-PIP mediated epigenetic 
activation of certain genes. Recently, a SAHA-PIP termed `K` was shown to be the 
first-ever small molecule to enforce transcriptional activation of meiosis-regulating 
germ cell genes in a human somatic cell (Fig. 2C). It is important to note here that the 
meiotic process is specific to germ cells and could not occur in a somatic cell.108 
(Fig. 2) 
 As shown before, both HDACi and PIPs were individually shown to be 
successful in treating neurodegenerative disorders but with certain disadvantages. 
Hence, conjugating them both to generate other HDACi-PIP could lead to site-
specific activation of genes associated with memory formation and neurodegeneration. 
Recently, a SAHA-PIP called `M` was shown to distinctively activate a set of 
neurotransmitter genes including NRXN and GPRC5B (Fig. 2D).109 SAHA-PIP `G` 
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activated the neurogenesis related GPC3 while SAHA-PIP `P` activated BDNF (Fig. 
2E). Interestingly, SAHA-PIP `W` specifically activated the ataxia related ATCAY 
gene (Fig. 2F).109  Synthetic PIPs are advantageous over other natural DNA-binding 
proteins as effective transcriptional activators because they possess flexible covalent 
sites and can bind to the methylated DNA sequences and disrupt the packed 
chromatin structure.110 Conjugation of a PIP with another HDACi conjugate called 
JAHA, which is HDAC8 specific also elicited similar promoter specific function.111 
Thus, it is possible to conjugate HDACis like BML-210, DNMTis like 5-azacytidine, 
and other such enzyme inhibitors to PIPs to have variable effects. Although it is 
difficult to predict the off-rate of PIPs inside the cells, the high binding affinity of 
SAHA-PIP to target DNA sequences and their ability to induce pluripotency genes 
even at 72 h and 100 nM concentration suggest it to be slow.112,113 Ligands that 
specifically recognize 15-16 base pairs like a PIP dimer was shown to target the 
regulatory region of the HIV-1 genome.114 Interestingly, a recent report suggests that 
partial cellular reprogramming promotes efficient neuroregeneration.115 In this regard, 
development of multi-gene targeting molecules like SAHA-PIPs could aid in the 
generation of clinically relevant neural cells.  
      Cell permeability is both an advantage and bottleneck of the PIPs as both the 
molecular size and pyrrole/imidazole content of the PIPs were shown to hamper its 
ability to permeate cells.100 But recent studies have shown that it is possible to 
increase the permeability of PIPs by engineering their chemical architecture.116 
Although PIPs are well characterized to influence gene expression in cell culture, 
their clinical translation requires comprehensive characterization of their 
pharmacokinetic (PK) profiles and ADME properties. Fukasawa et al. have shown 
through intravenous administration of a set of PIPs in rat models, that the area under 
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the plasma concentration-time curve increases linearly as a function of dose, and the 
systemic clearance and the volume distribution in the steady state remain unaltered.117 
Synold et al. have suggested that size or minor structural modifications of PIPs could 
affect their solubility and could lead to their accumulation in the lungs.118 Although 
SAHA does not hinder the binding properties of PIPs, it is tough to generalize 
whether HDACi-PIPs will have the same properties as PIPs. Because the PK profiles 
and ADME properties of the PIPs showed that various results were obtained with 
minor changes to the structures, therefore there is the need for a case-by-case study 
before employing the PIPs and/or HDACi-PIPs. 
 
4.2. Signalling pathway inhibitors  
The design of innovative small molecules that could effectively modulate intricate 
signalling factors can be useful to restore cellular homeostasis. Recently, a compound 
called Fisetin (Fig. 3A) was found to be an orally active, neuroprotective, cognition-
enhancing small molecule. Fisetin possesses antioxidant activity and increases the 
intracellular level of glutathione and it has both neurotrophic and anti-inflammatory 
activity.119 Silivia et al. recently demonstrated CHF5074, a multifunctional anti-
inflammatory derivative as a novel anti Alzheimer compound in TG2576 mice.120 
Several synthetic compounds are capable of a synergistic effect on multi-targets 
associated with a particular signalling pathway. For example, effective inhibitors of 
acetylcholinesterase (AChE) and Monoamine oxidase such as imino 1, 2, 3, 4-
tetrahydrocyclopent[b]indole carbamates (Fig. 3B), Coumarin derivatives	 (Fig. 3C), 
chromone derivates	 (Fig. 3D), Lipocrine (Fig. 3E) to i) target the catalytic activity 
of AChE, ii) inhibit the AChE- induced Aß aggregation and iii) to protect against 
reactive oxygen species (ROS).	 Likewise, Caproctomine (Fig. 3F) prevented the 
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AChE- induced Aß aggregation and stimulated the cholinergic activity by 
antagonizing the muscarinic M2 receptor.121 Bolognesi et al. showed the derivatives of 
bis-tacrine (Fig. 3G) as the likely candidates for AD treatment as they could reverse 
the AChE-induced amyloid fibrillogenesis by inhibiting the AChE activity and 
chelating the metal ions.122 Rosini et al. developed a multi-target directed ligand 
carbacrine (Fig. 3H) to treat AD neurodegeneration by effectively blocking the in 
vitro AChE- induced Aß aggregation, decreasing the oxidative stress and 
antagonizing the NMDA receptor activity.123 Memoquin (Fig. 3I) is another multi-
target molecule capable of inhibiting acetylcholinesterase and β-secretase-1activity. 
Capurro et al. showed that Memoquin could enhance cognition and prevent the Aβ-
induced neurotoxicity in diseased mouse models.124 Youdim et al. prepared multi 
target drugs Ladostigil (Fig. 3J) and M30 (Fig. 3K), the derivatives of Rasagiline and 
demonstrated an improved effect on the depression, dementia and behavioral 
abnormalities related to AD in mouse models. M30 exhibited the neurorestorative 
activity and induced the production of BDNF and glia-derived neurotrophic factor.125 
Lu et al. have designed and synthesized the derivatives of resveratrol as a candidate 
for AD treatment that has the ability to inhibit Aß aggregation. One of the derivatives 
5d (Fig. 3L) showed no toxicity in a mouse model and in vitro studies have shown 
that the drug can enter the blood brain barrier.126  
      Small molecules capable of inhibiting epigenetic enzymes like HDAC and 
signalling pathway factors can have better efficacy. CUDC-907 is one such 
compound that has been designed with dual inhibitory activity against not only 
HDAC enzymes but also phosphatidylinositol 3-kinase (PI3Ks) (Fig. 3M).127 When 
compared with equivalent single target molecules, CUDC-907 displayed better 
growth inhibition in both cultured and implanted cancer cells by inhibiting class I and 
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II HDAC enzymes as well as the PI3K-AKT-mTOR pathway and signaling molecules 
(including MEK, RAF (a protein oncogene protein kinase), STAT-3 (Signal 
transducer and activator of transcription), and MAPK (Mitogen activate protein 
kinase)) and the upstream receptor tyrosine kinases. Developing such dual inhibitory 




5.  Conclusion and future perspective 
Small molecules are often referred to as the missing link in the central dogma of 
biology.1 Recent developments in bioinformatics and techniques such as diversity-
oriented synthesis suggest that it is possible to design small molecules to treat the 
diseases that were previously thought to be incurable. In general, diseases are 
characterized by dysregulation in the transcriptional machinery that maintains the 
cellular homeostasis. LTP governs a multitude of brain functions such as learning and 
memory. Small molecules that alter the chromatin architecture and signal transduction 
have shown clinical potential to modulate LTP mechanisms. However, to achieve 
effective regulation, artificial transcriptional activators capable of orchestrating a 
target gene network need to mimic its natural equivalents. By taking cues from nature, 
development of novel types of compounds like HDAC-PIPs, CUDC-907, CHF5074 
and others (Fig. 3) could open up exciting opportunities to precisely orchestrate the 
intricate transcriptional machinery conferring to memory. However, precaution 
should be taken to develop such strategies because chromatin remodelling and 
signalling pathways are not secluded events. Moreover, factors such as practicality 
and genome-wide specificity need to be focused to avoid side effects. Drugability is 
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another major factor that needs consideration, as physicochemical characteristics, 
DMPA properties and safety profiles of these multi-target molecules could hamper 
the development of such molecules. Strategies to make the sequence-specific 
epigenetic activators and/or signalling inhibitors to penetrate CNS are another major 
issues that need profound study. Some of the factors such as target-target interactions, 
different requirements for the percentage and duration of target engagement for 
different targets should also be considered.  Because interaction of one target could 
affect the signaling of another target, while the activation/inhibition of multiple 
targets could result in synergic toxic effects. Innovative strategies to generate multi-
target molecules with tunable activation potentials of differing strengths by taking the 
above-mentioned factors into account can lead to effective treatment of complex 
neurological disorders as illustrated in Fig. 4. 
(Fig. 4) 
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Next-generation synthetic genetic ON switches: Sequence-specific small molecules 
capable of modulating epigenetic enzymes like DNA methyl transferase (DNMT), 
histone deacetylases (HDAC) and signalling pathway factors can precisely turn `ON` 
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Fig. 1. A person with memory loss (Brain and neuron in grey) has a heterochromatin 
architecture protected by HDAC in which memory-associated gene(s) are silenced. 
HDACi treatment improves the memory (Brain and neuron in orange) through 












Fig. 2. (A) Creation of a DNA-based epigenetic switch. An innovative small molecule 
called SAHA-PIP capable of accessing both genetic and epigenetic environment got 
achieved by conjugating sequence-specific hairpin pyrrole imidazole polyamides 
(PIPs) with chromatin modifying histone deacetylases inhibitor SAHA. (B) Biological 
activity of SAHA-PIP in mouse cells. SAHA-PIP E could cause site-specific 
acetylation by hindering the HDACs only in the promoter of Nanog in mouse 
fibroblasts.  SAHA-PIPs D, J and O for c-Myc, Sox2 and Klf4 is also shown. 
Advanced version of SAHA-PIP δ induces site-specific chromatin remodelling of 
Oct-3/4 to trigger the core pluripotency gene network. (C) Biological activity of 
SAHA-PIP in human cells. SAHA-PIP K trigger unusual switching ON of the germ 
cell genes in a human somatic cell. (D) SAHA-PIP M trigger neurotransmitter related 
gene network. (E) SAHA-PIP G and P trigger neurogenesis related genes (GPC3 and 

























Fig. 3. Chemical structure of (A) Multi-target neuroprotective compound Fisetin, 
Amyloid β-aggregation inhibiting multi-target compounds like (B) imino 1, 2, 3,4-
tetrahydrocyclopent[b]indole carbamates, (C) Coumarin derivatives, (D) Chromone 
derivates, (E) Lipocrine, (F) Caproctomine, (G) Bis-tacrine derivatives, (H) 
Carbacrine, (I) Memoquin, (J) Ladostigil, (K) M30 and  (L) Resveratrol derivative. 
(M) A schematic representation of how the functional groups for inhibitory activity 






















Fig. 4. (A) Some major factors responsible for LTP induction are shown. (B) Next-
generation small molecules encompassing multi-functional properties (DNA binding 
domain (DBD) and modulators of factors conferring to signalling pathway and 
epigenetic enzymes) may effectively target the set of genes associated with LTP. The 
potential gene targets for LTP are represented as bowling balls and the compound 












Table 1 | LTP-associated genes and their function in human and animal models  
LTP-associated gene / 
factor 
Function Model Reference 
CREB Positive regulation of memory consolidation by modulating BDNF expression 
by binding to CRE 
Mice 12 
BDNF Positively modulates stable long-term potentiation (LTP) in hippocampus 
through TrkB receptor 
Mice 48 
Zif268 (EGR1) Strengthening of memory trace by regulating proteins in the amygdala region Mice 49 
Arc Govern the key translation factors during LTP consolidation Rat 50 
GAP43 LTP persistence through release of glutamate by PRKCA mediated 
phosphorylation of GAP43 
Rat 51 
Reelin Signal transduction through Apoer2 for the induction of LTP Mice 52 
Synapsin I Contributes to LTP by increasing the release of neurotransmitter and number of 
post synaptic neurons 
Rat 53 
Neurotensin Regulation of working memory Homo sapiens 54 
DLG3 Interaction with NMDA receptor and plays an important role in LTP and 
memory formation 
Mice 55 
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